A. Philotheou

发表

Insulin detemir lowers the risk of hypoglycaemia and provides more consistent plasma glucose levels compared with NPH insulin in Type 1 diabetes

S. Heller, S. Heller, G. Perriello, 2006, Diabetic medicine : a journal of the British Diabetic Association.

Efficacy and Safety of Liraglutide Added to Capped Insulin Treatment in Subjects With Type 1 Diabetes: The ADJUNCT TWO Randomized Trial

I. Hirsch, T. Pieber, C. Mathieu, 2016, Diabetes Care.

Comparable efficacy and safety of insulin glulisine and insulin lispro when given as part of a Basal-bolus insulin regimen in a 26-week trial in pediatric patients with type 1 diabetes.

T. Danne, S. Arslanian, A. Philotheou, 2011, Diabetes technology & therapeutics.

No Effect of the Altered Peptide Ligand NBI-6024 on β-Cell Residual Function and Insulin Needs in New-Onset Type 1 Diabetes

A. Ziegler, A. Philotheou, R. Jimenez, 2009, Diabetes Care.

Biphasic insulin aspart vs. human insulin in adolescents with type 1 diabetes on multiple daily insulin injections

H. Mortensen, M. Kocova, A. Philotheou, 2006, Pediatric diabetes.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

E. Renard, S. Garg, S. Heller, 2012, The Lancet.

Insulin glargine metabolite 21A‐Gly‐human insulin (M1) is the principal component circulating in the plasma of young children with type 1 diabetes: results from the PRESCHOOL study

R. Becker, T. Danne, A. Philotheou, 2015, Pediatric diabetes.

Insulin degludec in combination with bolus insulin aspart is safe and effective in children and adolescents with type 1 diabetes

T. Danne, V. Iotova, J. Silverstein, 2015, Pediatric diabetes.

Long-term efficacy and safety of insulin detemir compared to Neutral Protamine Hagedorn insulin in patients with Type 1 diabetes using a treat-to-target basal–bolus regimen with insulin aspart at meals: a 2-year, randomized, controlled trial

A. Philotheou, M. Bogoev, J. Larsen, 2008, Diabetic medicine : a journal of the British Diabetic Association.

Comparison of insulin detemir and insulin glargine in subjects with Type 1 diabetes using intensive insulin therapy

T. Pieber, M. Gall, A. Philotheou, 2007, Diabetic medicine : a journal of the British Diabetic Association.

A randomized trial comparing the rate of hypoglycemia—assessed using continuous glucose monitoring—in 125 preschool children with type 1 diabetes treated with insulin glargine or NPH insulin (the PRESCHOOL study)

T. Danne, A. Philotheou, Lin Ping, 2013, Pediatric diabetes.

Insulin degludec, an ultra-longacting basal insulin, versus insulin glargine in basal-bolus treatment with mealtime insulin aspart in type 1 diabetes (BEGIN Basal-Bolus Type 1): a phase 3, randomised, open-label, treat-to-target non-inferiority trial

E. Renard, S. Garg, S. Heller, 2012, The Lancet.